Periodic Reporting for period 3 - NANOFACTURING (The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals)

One of the major limiting factors for the further development of nanomedicines is the lack of facilities in the EU for the manufacture of such products in compliance with cGMP and at a scale commensurate with supplying a clinical trial program through to complete proof of...